IsoRay Inc. has signed an agreement with BrachySciences a division of Biocompatibles International plc to distribute IsoRay's Proxcelan Cesium-131 brachytherapy seeds.

Dwight Babcock, IsoRay chairman and CEO, commented, "We are very pleased to announce this collaboration with BrachySciences. Management believes this distribution agreement will enable us to increase the sales of Cesium-131 within the prostate cancer therapy market. This supports our ongoing strategy of driving sales by adding an additional outside distribution channel to augment our current sales staff. We look forward to a close working relationship with BrachySciences that will help us further penetrate the brachytherapy market."

IsoRay remains committed to bringing innovative products and services to the brachytherapy market in support of our physicians. We believe that this agreement will provide our physicians greater choice and flexibility in offering their patients the newest isotope available.

"BrachySciences is committed to providing the most innovative products and technologies to physicians performing prostate brachytherapy", said Jim Matons, president of BrachySciences. "We are delighted to have signed an agreement with IsoRay that will allow us to offer our physicians Cesium-131. We believe that with the combination of our highly experienced sales team and our latest delivery technologies, we are ideally positioned to expand the use of this unique isotope."

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to treat prostate and other cancers.